Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study

Background: Crizanlizumab is a novel inhibitor of P-selectin, a key player in multicellular adhesion and inflammatory signaling, that leads to vaso-occlusion in sickle cell disease (SCD). Objectives: The SOLACE-adults study evaluated the pharmacokinetics, pharmacodynamics (P-selectin inhibition), sa...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Julie Kanter, Sarah Mennito, Santosh M. Nair, Deepa Manwani, Abdullah Kutlar, Nirmish Shah, Deborah Keefe, Hariprasad Madhamshetty, Michele Nassin, Evgeniya Reshetnyak, Anisha E. Mendonza, Darla Liles
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	SAGE Publishing 2024-11-01
سلاسل:	Therapeutic Advances in Hematology
الوصول للمادة أونلاين:	https://doi.org/10.1177/20406207241292508
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!